HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $13 price target.
Stocks · News reference
Reported Earlier, Telix Names David Gill Board Chair As Mark Nelson Steps Down From Interim Role
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix" or the "Company") today announces that David Gill has been appointed Chair of the Board, effective immediately.Mr. Gill joined Telix as a
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M Estimate
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 0 percent. This is a 47.83 percent increase over losses of $(0.23) per share from the same
Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est
Evolus (NASDAQ:EOLS) raises FY2026 sales outlook from $327.000 million-$337.000 million to $330.000 million-$337.000 million vs $330.445 million estimate.
Telix Pharmaceuticals shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $20 price target.
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.